Professor James Lindsay, FRCP PhD BM BCh

Profile

James Lindsay is the Professor of Inflammatory Bowel Disease at Barts and the London School of Medicine and Dentistry, Queen Mary University of London and a Consultant Gastroenterologist at Barts Health NHS Trust. Along with a full multidisciplinary team he runs the adolescent and adult IBD service at The Royal London Hospital. He is the Education Officer and a member of the Governing Board of the European Crohn’s and Colitis Organisation (ECCO). He is also the ECCO e-learning ambassador and past chair of the ECCO Education Committee. He has chaired working groups for the ECCO consensus on the management of Crohn’s disease and ulcerative colitis. He is the British Society of Gastroenterology (BSG) national societies representative to United European Gastroenterology.

Teaching

Professor Lindsay is the IBD module director for the MSc in Gastroenterology

Research

Research Interests:

Professor Lindsay serves on the BSG IBD Clinical Trials Steering Group and is Chief Investigator for a series of investigator-led and commercial clinical trials in IBD. He leads the NIHR funded ASTIClite trial which will assess the efficacy, safety and mechanism of action of low intensity autologous stem cell transplantation in patients with refractory Crohn’s disease. In addition, he jointly supervises two translational research programmes: one focusing on antigen presentation and cell trafficking within the mucosal immune system (in collaboration with Dr Andy Stagg), and the other studying the role of microRNA profiles to direct phenotype in IBD (in collaboration with Prof Andy Silver).

Publications

1. Effects of Low-FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.Cox SR, Lindsay JO, Fromentin S, Stagg AJ, McCarthy NE, Galleron N, Ibraim SB, Roume H, Levenez F, Pons N, Maziers N, Lomer MC, Ehrlich SD, Irving PM, Whelan K. Gastroenterology. 2020 Jan;158(1):176-188.e7. doi: 10.1053/j.gastro.2019.09.024. Epub 2019 Oct
   
2. Staudacher HM, Lomer MCE, Farquharson  FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K. Low FODMAP diet and probiotics in irritable bowel syndrome: a 2x2 factorial design, randomised, placebo-controlled trial. Gastroenterology. 2017 Oct;153(4):936-947. doi: 10.1053/j.gastro.2017.06.010. Epub 2017 Jun 15
   
   
3. Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J, Farge D, Hawkey CJ. Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):399-406. doi: 10.1016/S2468-1253(17)30056-0. Epub 2017 Apr 6
   
   
4. Hawkey CJ, (Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G), Rovira M, Satsangi J, Danese S, Russell N, Gribben J, Johnson P, Larghero J, Thieblemont C, Ardizzone S, Dierickx D, Ibatici A, Littlewood T, Onida F, Schanz U, Vermeire S, Colombel JF, Jouet JP, Clark E, Saccardi R, Tyndall A, Travis S, Farge D.  Autologous haematopoietic stem cell transplantation for refractory Crohn’s disease: a randomised clinical trial. JAMA. 2015 Dec 15; 314(23):2524-34
   
   
5. Hedin C, van der Gast CJ, Rogers GB, Cuthbertson L, McCartney S, Stagg AJ, Lindsay JO, Whelan K. Siblings of Crohn's disease patients exhibit a biologically relevant dysbiosis in the mucosal microbiota. Gut, 2016 Jun;65(6):944-53

All Publications

Supervision